New players on the patent chess board

The advent of inter partes review (IPR) proceedings under the America Invents Act (AIA) has introduced new players to the traditional patent litigation scene in the US. Among others, new entrants range from not-for-profits, with ideological motivations, to for-profit entities leveraging IPRs for financial gain.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent

New players on the patent chess board

Editor's picks

Editor's picks

More features